Work

Changes in bone density and metabolism marker levels in type I Gaucher's disease following annual zoledronic acid hydrate administration: A case report

Year: 2026

Type: article

Abstract: We present a rare case of type I GD with frequent bone complications. After multiple fractures the patient received 5 mg zoledronic acid hydrate, which improved TRACP-5b and P1NP levels. After 1 year, TRACP-5b levels increased significantly, and the patient received SRT therapy complemented with eldecalcitol for vitamin D deficiency. One year later, bone density had improved and bone metabolism markers remained within normal levels. Osteoporosis treatment is a potential strategy for GD-related bone symptoms.

Source: Bone Reports

DOI: 10.1016/j.bonr.2026.101962

Authors: Hiroyuki Onuma, Naoki Haraguchi

Institutions: St. Marianna University School of Medicine, Kawasaki Municipal Tama Hospital

Language: English

Topic: Lysosomal Storage Disorders Research

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,540